What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

about

What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Item

http://www.wikidata.org/entity/Q55023835

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

What is the risk-benefit ratio ...... in people with schizophrenia?

@en

What is the risk-benefit ratio ...... in people with schizophrenia?

@nl

type

Item

label

What is the risk-benefit ratio ...... in people with schizophrenia?

@en

What is the risk-benefit ratio ...... in people with schizophrenia?

@nl

prefLabel

What is the risk-benefit ratio ...... in people with schizophrenia?

@en

What is the risk-benefit ratio ...... in people with schizophrenia?

@nl

P1476

What is the risk-benefit ratio ...... in people with schizophrenia?

@en

P2093

Christoph U Correll

http://www.w3.org/2001/XMLSchema#string

John M Kane

http://www.w3.org/2001/XMLSchema#string

P2860

The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor

A Systematic Review of Mortality in Schizophrenia

Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy

Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium

A systematic review and meta-analysis of recovery in schizophrenia

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives

Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

P304

149-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/WPS.20516

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jose M Rubio

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29856543

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

5980517

http://www.w3.org/2001/XMLSchema#string